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ABSTRACT
Introduction: Recent studies indicated tumors may be comprised of 
heterogeneous molecular subtypes and incongruent molecular portraits may emerge 
if different areas of the tumor are sampled. This study explored the impact of intra-
tumoral heterogeneity in terms of activation/phosphorylation of FDA approved drug 
targets and downstream kinase substrates.
Material and methods: Two independent sets of liver metastases from colorectal 
cancer were used to evaluate protein kinase-driven signaling networks within different 
areas using laser capture microdissection and reverse phase protein array. 
Results: Unsupervised hierarchical clustering analysis indicated that the signaling 
architecture and activation of the MAPK and AKT-mTOR pathways were consistently 
maintained within different regions of the same biopsy. Intra-patient variability of the 
MAPK and AKT-mTOR pathway were <1.06 fold change, while inter-patients variability 
reached fold change values of 5.01. 
Conclusions: Protein pathway activation mapping of enriched tumor cells obtained 
from different regions of the same tumor indicated consistency and robustness 
independent of the region sampled. This suggests a dominant protein pathway 
network may be activated in a high percentage of the tumor cell population. Given 
the genomic intra-tumoral variability, our data suggest that protein/phosphoprotein 
signaling measurements should be integrated with genomic analysis for precision 
medicine based analysis.
INTRODUCTION
The implementation of precision cancer therapy 
based on the underpinning individualized molecular 
profile of each tumor has become the new paradigm in 
oncology with a significant number of new precision 
drugs receiving approval from the US Food and Drug 
Administration (FDA) every year. This targeted approach 
has shown promising results especially when patients 
are allocated to different treatment options based on the 
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molecular characteristics of the tumor [1-9]. Nearly all 
precision medicine clinical studies utilize core needle 
biopsies or fine needle aspirates as the preferred tissue 
collection method due to their relatively non/low-invasive 
nature compared to surgical excision. However, recent 
studies have indicated that tumors are characterized 
by significant inter- and intra-tumoral molecular 
heterogeneity. As a consequence, a different molecular 
architecture may emerge when different areas of the tumor 
are sampled or when primary tumors are compared to 
matched metastatic lesions [10-21]. Therefore, if tumors 
are indeed heterogeneous at the genomic clonal level, is a 
single biopsy sufficient to determine the most appropriate 
course of treatment for any given patient? 
Because genomic instability is a characteristic 
of cancer cells, whether the heterogeneity observed is 
largely based on variability of “passenger” alterations 
(not causally significant for the tumorigenic process nor 
under selective pressure) and whether these alterations are 
a cause or consequence of the tumorigenic process still 
remains unclear [22]. While most of the recent studies 
exploring molecular heterogeneity have relied on genomic 
analyses, functional protein signaling events, largely 
driven by phosphorylation, are the actual drug targets of 
many of the new precision therapies (e.g. kinase/enzyme 
inhibitors). Consequently, the analysis of the complex 
protein-signaling network of tumor cells remains a 
central element for better understanding the impact that 
tumor heterogeneity has on the selection of treatment 
for cancer patients. For these reasons, it is critical to 
understand if  protein-based data generated form different 
regions of the same sample are robust and consistent. 
Thus far relatively few studies have focused on the tumor 
molecular heterogeneity of the proteome and especially 
on the kinome/phosphoproteome,  [12, 23-26]. Moreover, 
protein analysis of tumor tissue performed in the past 
under the auspices of tumor heterogeneity evaluation, have 
failed to utilize upfront cellular enrichment/purification 
techniques such as Laser Capture Microdissection (LCM). 
Such approaches are necessary to eliminate confounding 
analytical variability of different cellular populations (e.g. 
epithelial cells, endothelial cells, lymphocytes, fibroblasts, 
nervous structures etc.), along with the inability to predict 
the level of any given protein/phosphoprotein in a specific 
cell subpopulation [27]. 
A number of studies have already demonstrated that 
the molecular landscape of metastatic lesions significantly 
differ from primary tumors [13-21]. Indeed, systemic 
alterations in the phosphoprotein driven signaling 
architecture appear early in the tumorigenic process, 
such as in breast cancer and skin cancer studies [28,29]. 
However, the development of metastatic lesions is the 
main cause of cancer related-death, and most precision 
medicine trials are currently evaluating the molecular 
profile of the metastatic lesions directly to identify 
“actionable” alterations to be tailored by the new anti-
cancer compounds. Moreover, due to its proximity in the 
vascular tree, the liver is one of the most common sites of 
metastasis for a variety of cancers such as CRC, breast, 
ovary, and it is one of most accessible visceral sites to 
biopsy with relatively low morbidity. With an eye towards 
applications in the context of precision medicine based 
molecular profiling and with these reasons as context, we 
sought to explore the nature of intra-tumoral variability 
in the context of protein/phosphoprotein signaling with 
a focus on “actionable” cell signaling pathways using 
hepatic metastasis from colorectal cancer (CRC) as a 
model for future, expanded analysis. Reverse Phase 
Protein Microarray (RPPA) coupled with LCM was used 
to assess the expression/activation level of selected targets 
for FDA approved compounds and downstream substrates 
across different regions of a metastatic lesion. Previous 
findings from our group have identified the AKT-mTOR 
pathway as highly activated in liver metastases from CRC 
compared to matched primary tumors along with a number 
of Receptor Tyrosine Kinases (RTKs) and the downstream 
substrate ERK [16]. For these reasons we further explored 
changes within the MAPK and the AKT-mTOR pathway 
across different areas of the same lesion.
RESULTS
Analysis of the signaling architecture of study set 
1
Study Set 1 included 6 surgical specimens with an 
average diameter of 2.5 cm. Only a portion of the original 
specimen (average of 1.4 cm) was used for this analysis. 
Tumor epithelial cells collected from two different areas 
of the same lesion were compared within and across 
patient(s). In all instances, the two areas analyzed (named 
“A” and “B” respectively) were separated by an average 
of 5 mm of tissue (Figure 1A). Unsupervised hierarchical 
clustering analysis was initially performed to evaluate the 
overall signaling architecture of two different areas of the 
same lesion. 
The 56 proteins/phosphoproteins measured in the 
first study set showed that in 4 of the 6 (67%) paired 
samples the overall signaling architecture was maintained 
across the different areas of the same tumor (Figure 2A). 
Because the data seemed to be driven mainly by the two 
samples with overall high signal (sample 6b and 4a), the 
unsupervised hierarchical clustering analysis was repeated 
after the two samples were removed; the second analysis 
was consistent with the original findings (Supplementary 
Figure 1).
The analysis was then limited to proteins that 
are drug targets and downstream enzymatic substrates 
of either FDA approved targeted kinase inhibitors or 
experimental agents under investigation in clinical trials: 
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the MAPK and the AKT-mTOR signaling pathways. As 
shown in Figure 3A and 3B, two distinct clusters were 
detected for both the MAPK and the AKT-mTOR pathway 
with one group of patients showing high activation of the 
druggable targets and substrates, and the second group 
presenting with low activation. Since high and/or low 
levels of drug target activation would likely be used to 
stratify patients to a targeted treatment, for each patient 
we evaluated how many times paired specimens were 
contained within the same cluster (e.g. group a and b). 
For the MAPK pathway all matched pairs were contained 
in the same group (Figure 3A), while for the AKT-mTOR 
pathway, 4 of the 6 matched paired (66.6%) where 
included in the same cluster (Figure 3B). 
To further investigate the role of tumor heterogeneity 
at the signaling level, fold changes between and within 
patients were evaluated for both pathways (Figure 4A). 
Fold changes for the MAPK pathway ranged between 
0.04-0.73 within the same lesion and reached values of 
5.06 when lesions from different patients were compared. 
Intra-patient fold change for the AKT-mTOR pathway was 
below 0.7 for 5 of the 6 cases, while it was between 0.01 
and 3.57 across patients.
Analysis of the signaling architecture of study set 
2
Study Set 2 included metastatic lesions from 9 
patients (Figure 1B). Immediately after surgical excision, 
two separate areas were isolated from each metastasis 
using 18-, 16- and 14- gauge needle. Samples were stored 
and processed independently. The average dimension 
of the metastases was 2.6 cm and the average distance 
between the two areas analyzed was 1.4 cm. 
Unsupervised hierarchical clustering analysis 
of the activation/phosphorylation state of the 33 drug 
targets measured in study set 2 revealed that 5 of the 9 
matched pairs (55.5%) were contained within the same 
cluster (Figure 2B). As shown for study set 1, when the 
unsupervised analysis was limited to the MAPK and AKT-
mTOR pathway, distinct clusters were detected based on 
the activation level of the different components of the 
module (Figure 3C and 3D). Four different clusters were 
identified for the MAPK pathway. The first cluster (group 
a) included 4 samples characterized by high activation 
of MEK. Of the four samples included in this group, 
two belonged to the same specimen. The second cluster 
Figure 1: Sample collection and LCM-RPPA work flow. For study set 1 two areas of the same specimen, separated by an average 
distance of 0.5 cm, were analyzed (A). For study set 2, two distinct areas, separated by an average of 1.4 cm, were harvested by a certified 
pathologist after surgical removal of the metastatic lesion and processed separately (B).
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(group b) showed overall low activation of the MAPK 
pathway. Of the seven samples included in this cluster, 
six belonged to matching pairs. The third cluster (group 
c) was characterized by increased activation of BRAF 
only; two matched pairs were grouped within this cluster. 
Finally the last cluster (group d) showed increased overall 
activation of the pathway. Of the three samples included 
in this group, two were collected from the same specimen.
Similarly, three major clusters were found for the 
AKT-mTOR pathway module. The first group (group a) 
showed an overall partial activation of the pathway. Of the 
three samples included in this first cluster, two belonged 
to the same patient. A large cluster with overall low 
activation of the pro-survival pathway included 11 samples 
(group b), 10 of which belonged to matching pairs. Finally 
group c showed high activation of the rapamycin target 
mTOR and direct downstream substrate p70S6K. A total 
of four samples collected from two patients were included 
in this cluster. Also in this case, intra-tumor heterogeneity 
in terms of fold change between matched pairs ranged 
between <0.01 and 1.06 for the MAPK pathway and 
between 0.03 and 1.04 for the AKT-mTOR pathway. Inter-
tumor heterogeneity fluctuated between 0.13 and 2.62 
for MAPK pathway and 0.45 and 3.76 for AKT-mTOR 
pathway (Figure 4B). 
Figure 2: Unsupervised hierarchical clustering analysis for the full set of analytes measured for study set 1 and 2 (A and B). 
On the x-axis are listed the protein/phosphoprotein measured (56 and 33 respectively for study set 1 and 2). On the y-axis are reported the 
samples; same color was used for each pair of matched samples.
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DISCUSSION
The recent discussions concerning intra-tumoral 
heterogeneity and clonal expansion has opened a new 
debate on the validity of selecting targeted treatment(s) 
for cancer patients based on a single tissue biopsy [30]. 
Given the limitations of safe tissue collection for precision 
medicine trials, especially from patients with metastatic 
disease, it is important to understand biopsy-to-biopsy 
and intra-biopsy molecular variations. For example, 
we do not know whether the dominant activated signal 
pathways differ between tumor cells sampled at opposite 
ends of a core biopsy. If each tumor cell population has 
a characteristic dominant activated signal network that 
spans the whole population, then a single biopsy may 
be an accurate representation of the state of the whole 
heterogeneous tumor colony. On the other hand, if each 
part of the tumor is different, a set of biopsies would be 
required to collect a representative sample. In this study, 
we used an LCM-RPPA workflow to address this question 
with regard to the signaling architecture of metastatic 
lesions in the liver. 
A number of studies have demonstrated that biopsies 
collected from different areas of the same lesion and 
across lesions have substantial variability at the genomic 
level with the intra-tumoral heterogeneity being much 
Figure 3: Unsupervised hierarchical clustering analysis. Representation of the endpoints included in the MAPK and AKT-mTOR 
pathway modules for study set 1 (A and B) and 2 (C and D). 
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smaller then inter-tumoral heterogeneity [11-13,31-33]. 
Nonetheless, the impact of genomic heterogeneity on the 
proteome and its activation has not been deeply explored 
thus far [23-26,34,35]. An aspect of the current narrative 
concerning the intra-tumoral genomic heterogeneity 
observed in recent studies is whether a major contributor 
to the variability observed might be attributed to passenger 
genetic alterations that are not under selection pressure and 
thus vary more randomly across a given lesion. Because 
genomic studies may be unsuited for discriminating 
between drivers versus passenger alterations, we 
postulated that proteomic studies directly measuring the 
functional activation of the drug targets, themselves, may 
reveal new insight on the nature of inter- and intra-tumor 
heterogeneity.
The approach used in this study offers a number of 
attributes that distinguish it from previous work. First, 
the direct measurement of phosphorylated drug targets 
and downstream substrates provides a direct read-out 
on the functional signaling network of the tumor cells 
by providing information about which drug targets are 
truly activated and whether this activation is affecting the 
downstream members of the network. In vitro and in-/ex-
vivo analyses have shown that the direct quantification of 
the activation level of targeted proteins and effectors can 
successfully be used to predict the therapeutic effect of 
biological compounds [36-41]. Second, our study uniquely 
used LCM for upfront tumor epithelium isolation and 
enrichment, an approach that has never been used before 
to explore tumor heterogeneity. Previous studies focused 
on inter- and intra-tumor variability analyzed the whole 
tissue lysate without upfront tumor epithelial cell isolation 
[23,25,26,35]. A number of publications have shown that 
upfront cellular enrichment is necessary when conducting 
functional proteomics studies because the different 
cellular component of the tumor microenvironment can 
deeply influence the accuracy of the results [27,42,43]. 
Without this upfront cellular enrichment, it is impossible 
to clearly determine whether any changes seen across 
a specimen are due to tumor epithelium molecular 
heterogeneity or whether they are simply caused by the 
differences in the amount of fibroblasts, adipocytes, 
leucocytes, endothelial cells, and nerve cells across the 
specimen. Since important signaling drug targets like 
AKT, mTOR, ERK are ubiquitously found in every cell 
type at various concentrations, it is impossible to control 
for this co-variable without isolating the subpopulation of 
cells of interest from the outset. Finally, the unique tissue 
collection approach we utilized for this study, coupled 
to upfront cellular enrichment via LCM, allowed us to 
control for a number of pre-analytical variables that are 
known to impact the integrity of the phosphoproteome 
and proteome (e.g. time between sample collection and 
storage, type of fixation method etc. and uncontrolled 
cellular heterogeneity in the tissue input) [44]. For 
example, because the two areas analyzed in study set 
1 were isolated from the same cryosection via direct 
visualization under the microscope, this approach allowed 
us to control for variability in terms of collection time and 
storage across surgical specimens. The approach used for 
study set 2, on the other hand, allowed us to mimic sample 
collection under radiological guidance, a procedure that 
has become part of the standard of care of patients with 
metastatic disease. In addition, the two fragments analyzed 
Figure 4: Representation of intra-tumor heterogeneity and heterogeneity across patients. MAPK and mTOR pathway 
module were compared to assess the degree of heterogeneity within the same lesion (intra-patient variability) and across different patients 
(inter-patient variability) (A and B for study set 1 and 2 respectively). Fold change and standard error of the mean are shown for each protein.
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were collected concomitantly after surgical excision of 
the metastatic lesion to limit variability attributable to 
collection time. Despite the unique and novel aspects of 
our study sets, our conclusions are constrained by small 
sample sizes similar to recent studies [23], and thus will 
require further validation in larger study sets in order to 
draw definitive conclusions
Overall, these pilot data indicate that the activation 
level of a large panel of drug targets and downstream 
substrates is quite reproducible/stable across different 
areas of the same metastatic lesion, especially compared 
to the heterogeneity seen across different patients. These 
data imply that for each metastatic colony a single 
dominant signaling pathway may drive a majority of the 
cellular population, regardless of presumed genetic clonal 
heterogeneity. This may signify the existence of dominant 
driving signaling pathway within the metastatic colony. 
Nonetheless, while the tumor cells throughout a single 
metastasis may be similar, they may still be different from 
other metastasis in the same or different organs. Drake and 
colleagues have recently measured the activation level 
of a small panel of kinases within and across different 
metastatic lesions from castration resistant prostate cancer 
[23]. In concordance with our data, the analysis showed 
that the phosphorylation levels were maintained across 
different lesions collected from the same patient even for 
metastases that developed at different organ sites [23]. 
As expected, a greater variation in the activated kinome 
was observed between lesions collected from different 
patients indicating that the inter-patient variability is 
much greater than the changes within a single individual. 
Similarly, Malinowsky and colleagues have evaluated 
tumor heterogeneity in primary breast cancer and matched 
metastatic lymph nodes. The results indicated that different 
areas of the primary tumors as well as the metastatic 
lesions were heterogeneous; nonetheless the differences 
seen within the lymph node lesions were slightly smaller 
than the one measured across different areas of the 
primary tumors. Interestingly, when tumor variability 
was evaluated within different patients, the coefficient of 
variations were almost double compared to one measured 
in the intra-tumor analysis. This study used whole tissue 
lysates obtained from formalin-fixed paraffin-embedded 
(FFPE) tissue sections and analyzed by RPPA [25]. It is 
well known that fixation in formalin of different areas of 
the tumor is time dependent, and the signaling network of 
large FFPE specimens can vary across the different areas 
of the lesions based on the time of fixation. Finally, by 
using whole tissue lysates where samples are not enriched 
for tumor epithelia, the signaling network identified by this 
study cannot be attributed to the cancer cells directly, but 
rather is an average of all the different cell subpopulations 
present in the tissue (including immune cells, nerves, 
fibroblasts etc). Finally, a recent work sampling the same 
metastatic lesion longitudinally during targeted treatment 
showed reproducible intra-tumoral signaling architecture 
of non- target molecules across different points in time 
[45]. Even if sample collection was carried out over time 
under CT guidance, and as, consequence, different areas of 
the lesion were sampled and analyzed, the data indicated 
that the signaling network was robust not only across areas 
of the same lesions, but at different points in time.
Our study has limitations that need to be addressed 
through further investigations. Due to the low number of 
samples enrolled in the study, our data need to be validated 
on an independent set where multiple areas of the same 
lesions and different lesions are collected from a larger 
cohort of patients. Finally, the study sets only included 
liver metastasis from colorectal cancer. 
Despite the importance of liver metastasis in cancer 
progression, our analysis is obviously limited to a single 
organ site. The degree of heterogeneity in other metastatic 
sites such as bone, brain, chest wall, etc. are not addressed 
by our work. Moreover, while we interrogated the AKT-
mTOR and MEK-ERK signaling pathways due to their 
high importance as druggable targets, the degree of 
intratumoral heterogeneity in signaling activation in other 
drug target networks remains to be more deeply explored. 
Nonetheless, our profiling of 55 kinase drug targets did 
indicate an overall stable signaling architecture.
Other types of cancers may have a different degree 
of intra-tumoral variability at the signaling level and 
it could be that the variabilityility is influenced by the 
microenvironment of the organ-sites. Matching genomic 
profiling was not available for the two study sets analyzed, 
and direct evaluation of the genomic variability needs to 
be further investigated, especially in relationship to the 
protein kinase driven signaling data. While we focused 
our tumor heterogeneity analysis on the activation/
phosphorylation state of specific key signaling proteins, 
it is it is, unknown not know whether or not these protein 
pathways represent the functional/causal “drivers” of 
the tumor in any of the patients. Future studies that 
incorporate mulit-omic molecular analysis from multiple 
independent biopsies obtained from the metastatic lesion 
in the context of precision medicine studies with known 
clinical outcome will help to better define the impact of 
tissue heterogeneity.
This first protein-based drug target activation 
analysis of the tumor epithelium obtained from human 
metastatic lesions indicates that the activated signaling 
architecture is consistently observed within metastatic 
lesions collected from the same patient while each 
patient’s tumor has distinct patient-specific signaling 
portraits. Incorporating proteomic and phosphoproteomic 
profiling into the precision medicine workflow is both 
possible and could be synergistic with genomic analysis 
[46]. If validated on an independent set of samples, 
these results could be critically important for precision 
medicine applications, especially in the context of tissue 
requirements for accurate assessment of the underpinning 
molecular detail. 
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MATERIALS AND METHODS
Two independent study sets of liver metastases from 
CRC patients were evaluated in this analysis. Samples 
were obtained from the Centro di Riferimento Oncologico 
(Aviano, Italy), Istituto Regina Elena (Rome, Italy), and 
Istituto Nazionale Tumori (Milan, Italy) where sample 
collection was approved by the local IRB. Patients entered 
the study voluntarily and provided signed informed 
consent prior to sample collection. All samples were 
rapidly collected to minimize pre-analytical variables, 
snap-frozen, and stored at -80oC until the molecular 
analysis was performed.
Laser capture microdissection 
For each sample, 10 eight-micron cryo-sections 
were prepared. Tumor epithelial cells were isolated 
from the surrounding microenvironment using the 
ArcturusXT™ LCM System (Arcturus Bioscence, 
Mountain View, CA, USA). Approximately 10,000 to 
15,000 epithelial cells were isolated from each sample 
on CapSure Macro LCM caps (Arcturus Bioscence, 
Mountain View, CA, USA). In brief, slides were first fixed 
in 70% ethanol, washed in deionized water, stained with 
hematoxylin (Sigma, St. Louis, MO, USA) and Scott’s 
tap water substitute (Elec Micros Sci, Hatfield, PA, USA) 
followed by dehydration in 70%, 95%, 100% ethanol and 
xylene. To preserve post-translation modification such as 
phosphorylation, complete mini protease inhibitor tablets 
(Roche Applied Science, Indianapolis, IN, USA) were 
added to 70 % ethanol, deionized water, hematoxylin, 
and Scott’s tap water substitute. Microdissected cells 
were lysed in 1:1 solution of Tris-Glycine SDS sample 
buffer (Life Technologies, Carlsbad, CA, USA) and Tissue 
Protein Extraction Reagent (T-PER Pierce, Rockford, IL, 
USA) with 2.5% β-mercaptoethanol (Sigma, St. Louis, 
MO, USA) [27]. Cell lysates were boiled for 8 minutes 
and stored at -80°C until further processed. 
Reverse phase protein microarray
Array construction
Using a 2470 Aushon arrayer equipped with 185 μm 
pins (Aushon BioSystems, Burlington, MA), cell lysates 
were printed in triplicate onto nitrocellulose-coated slides 
(Grace Bio-Lab, Bend, OR). For quality control purposes, 
standard curves were printed on each array along with 
the samples. To quantify the amount of total protein in 
each sample, selected arrays were stained with Sypro 
Ruby staining solution (Molecular Probes, Eugene, OR) 
following manufacturing recommendation [47]. 
Immunostaining 
Before proceeding with immunostaining, arrays 
were first incubated in Reblot Stripping solution 
(Chemicon, Temecula, CA) for 15 minutes, washed 
twice with PBS (Life Technologies, Carlsbad, CA) and 
incubated in I-Block (Tropix, Bedord, MA) for one 
hour. Using an automatic system (Dako Cytomation, 
Carpinteria, CA), arrays were then incubated with 
commercially available 3% hydrogen peroxidase 
solution, avidin-biotin blocking system, and protein block 
(Dako Cytomation, Carpinteria, CA). The expression/
activation level of a panel of FDA approved and/or under 
investigation drug targets and their downstream effectors 
was measured using a single primary antibody targeting 
the protein and phosphorylation site of interest. Each 
antibody used on the array was previously validated using 
western blot to confirm its specificity [48]. Fifty-six and 
33 primary antibodies were used for study set one and two, 
respectively (Supplementary Table 1). A commercially 
available tyramide-based avidin/biotin amplification 
system (CSA; Dako Cytomation, Carpinteria, CA) and 
fluorescent detection (LI-COR Biosciences, Lincoln, NE) 
were used to quantify the amount of protein present in 
each sample. Antibody stained slides were scanned using 
the Tecan laser scanner (Tecan PowerScanner Tecan group 
Ltd., Männedorf, Switzerland). Images were analyzed 
with MicroVigene 5.1.0.0 (Vigenetech, Carlisle, MA) as 
previously described [46]. Because the output of the RPPA 
platform is quantitative, the intensity values obtained from 
the analysis were reported on a continuous variable. 
Statistical analysis
Unsupervised hierarchical clustering analysis was 
performed using JMP version 11 (SAS Institute Inc., 
SAS, Cary, NC). The impact of tumor heterogeneity in 
two major pathways commonly targeted in different solid 
tumors was then evaluated. The MAPK pathway module 
of study set 1 and 2 included B-Raf (S445), MEK 1/2 
(S217/221), Elk1 (S838) and Erk (T202/Y204). The AKT-
mTOR pathway module included mTOR (S2448) and its 
downstream substrates p70S6K (T389), S6 Ribosomal 
Protein (S240/244) and eIF4G (S1108) in study set one 
and mTOR (S2448), p70S6K (S371), S6Ribosomal 
Protein (S235/236) and eIF4G (S1108) in study set two. 
Pathway activation module scores for each sample were 
generated by summing the single individual value for each 
endpoint included in a given module. For the assessment 
of the intra-tumor heterogeneity, fold changes of the 
pathway activation score within the two samples of the 
same patient were evaluated. Fold change differences 
across patients were calculated using the average values 
derived from each matched pair. Average values were 
then normalized on the lowest value of the series. Data 
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were represented using bar graphs created with GraphPad 
version 5.0a (GraphPad Software, Inc., San Diego, CA). 
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